Results 61 to 70 of about 4,836 (184)

Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials [PDF]

IMPORTANCE The clinical effects of risankizumab (a monoclonal antibody that selectively targets the p19 subunit of IL-23) for the treatment of ulcerative colitis are unknown.
Parkes, Gareth, Sanchez Gonzalez, Yuri, Boland, Brigid S, Panaccione, Remo, Bossuyt, Peter, Kalabic, Jasmina, Ferrante, Marc, D'Haens, Geert, Cheng, Ling, Levine, Phillip, Atreya, Raja, Schreiber, Stefan, Chen, Su, Armuzzi, Alessandro, Duan, W Rachel, Neimark, Ezequiel, Wu, Kaichun, Biedermann, Luc, Loftus, Edward V Jr, Pivorunas, Valerie, Biedermann, Luc; https://orcid.org/, Wallace, Kori, Melmed, Gil Y, Rahier, Jean-François, Louis, Edouard, Shu, Lei, Loftus, Edward V, Hisamatsu, Tadakazu, Siegmund, Britta, Dewit, Olivier, D'Cunha, Ronilda, Colombel, Jean-Frederic, INSPIRE and COMMAND Study Group, INSPIRE and COMMAND Study, Peyrin-Biroulet, Laurent   +34 more
core   +1 more source

Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
No evidence of an increased risk of incident cancer or KC was observed with biologic versus non‐biologic systemic therapies or across the biologic classes evaluated. Abstract Background There are concerns that biologic therapies for psoriasis may increase cancer risk. Objectives To compare risks of (i) incident cancer excluding keratinocyte carcinomas (
Oras A. Alabas, Kayleigh J. Mason, Mark Lunt, Sarah Ryan, Nick J. Reynolds, Catherine H. Smith, Christopher B. Bunker, Christopher E. M. Griffiths, Adele C. Green, Richard B. Warren   +9 more
wiley   +1 more source

Efficacy and Safety of Risankizumab Among Patients With Ulcerative Colitis in East Asia: A Post Hoc Analysis of Two Randomized Clinical Trials

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim Risankizumab, a monoclonal interleukin 23p19 antibody, is a treatment for ulcerative colitis. This post hoc analysis reports the efficacy and safety of risankizumab for ulcerative colitis in patients in East Asia from the global phase 3 clinical trials. Methods In the 12‐week, phase 2b/3 induction study (NCT03398148), adults
Ken Takeuchi, Qian Cao, Keiji Ozeki, Sang‐Bum Kang, Jen‐Wei Chou, Madhuja Mallick, Tomoko Matsuda, Pierre A. Morisset, Jasmina Kalabic, Ronilda D'Cunha, Yuji Ogawa, Yafei Zhang, W. Rachel Duan, Yuh‐Ying Yeh, Tadakazu Hisamatsu   +14 more
wiley   +1 more source

Risankizumab i behandlingen av moderat til alvorlig psoriasis hos voksne

, 2022
Background: Psoriasis is a common chronic inflammatory skin disease with a considerable impact on quality of life. With their specificity and efficacy biologics are improving the outcome for patients with psoriasis in an outstanding manner.
Nilsen, Erik
core  

Sustained Remission of Pediatric Bowel‐Associated Dermatosis‐Arthritis Syndrome With Risankizumab

Pediatric Dermatology, EarlyView.
ABSTRACT Bowel‐associated dermatosis‐arthritis syndrome (BADAS) is a rare neutrophilic dermatosis characterized by recurrent fever, arthralgias, and skin eruptions, most commonly occurring in patients with inflammatory bowel disease. We report the case of a 17‐year‐old female with Crohn's disease who developed BADAS and achieved complete and durable ...
Kylie E. Peake, Harman Toor, Marie‐Christine Jean, Collin C. Barker, Joseph M. Lam   +4 more
wiley   +1 more source

Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study

, 2022
ObjectivePsA is a chronic disease with heterogeneous clinical manifestations requiring treatment options with long-term efficacy and safety. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA ...
Papp, Kim, Lars Erik Kristensen, Ann Eldred, White, Douglas, Soliman, Ahmed M., Keiserman, Mauro Waldemar, Eldred, Ann K., Barcomb, Lisa M., Lisa Barcomb, White, Douglas H.N., Lu, Wenjing, Papp, Kim A., Eldred, Ann, Ahmed M Soliman, Barcomb, Lisa, Mccasland, Leslie, Keiserman, Mauro, Leslie McCasland, McCasland, Leslie D., Wenjing Lu, Frank Behrens, Behrens, Frank, Kim Papp, Douglas White, Mauro Keiserman, Kristensen, Lars Erik   +25 more
core   +1 more source

Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Rheumatology and Therapy
Introduction Currently, the cause of psoriatic arthritis (PsA) is unknown, and the effectiveness of current drug treatments is unsatisfactory. In March 2019, the US Food and Drug Administration (FDA) approved risankizumab, a humanized immunoglobulin G1 ...
Qin-Yi Su, Hao-Nan Zhou, Guo-Mei Xia, Rui-Yuan Zhang, Hong-Yuan Tian, Chang Su, Yu-Xin Liu, He-Yi Zhang, Ting Cheng, Yue-Hong Huo, Qian Li, Sheng-Xiao Zhang   +11 more
doaj   +1 more source

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

International Journal of Dermatology, Volume 65, Issue 12, Page 2524-2531, December 2026.
This multicentre real‐world study illustrates the heterogeneity of systemic treatment approaches in erythrodermic psoriasis (EP) in Bavaria, Germany. Adverse events were more frequently observed with conventional therapies, whereas biologic therapies showed favorable outcomes.
Julian Kögel, Sandra Schuh, Julia Welzel, Michael Sticherling, Lukas Sollfrank, Carola Berking, Teodora Pumnea, Valerie Glatzel, Lars French, Felix Lauffer, Martin Valentin Vitus, Tilo Biedermann, Susanne Bauer, Michael Spindler, Mark Berneburg, Dennis Niebel   +15 more
wiley   +1 more source

Protocol for the Therapy Personalisation Using Multiomic Analyses in Inflammatory Bowel Disease (THAMES‐IBD) Study

JCC Plus, Volume 1, Issue 6, November 2026.
ABSTRACT Background Despite an expanding repertoire of advanced therapies for inflammatory bowel disease (IBD), treatment outcomes remain suboptimal, with only 30%–40% of patients achieving sustained remission. Emerging evidence indicates that therapeutic outcomes are shaped by complex interactions between host immune pathways, the gut microbiome and ...
John P. Thomas, Aamir Saifuddin, Sadek Malas, Meztli Matadamas Guzman, Cristina Di Poto, Dimple Dixit, Isabel Laszczak, H. Sophia Chung, Erik L. Allman, Yang Song, James L. Alexander, Bat‐Erdene Jugder, Ailsa Hart, Kyle Bednar, Nick Powell   +14 more
wiley   +1 more source

Rapid Efficacy of riSankizumab in pretibial psoriasis invOLVEment: RESOLVE [PDF]

Background: Despite extraordinary improvements in the management of psoriasis in recent times, some areas of the body, such as the pretibial area, still show an unsatisfactory response and a more significant impact on patient quality of life.
Nevena Skroza, Papini, Manuela, Gianmario Addis, Concetta Potenza, Riccardo Balestri, Nicoletta Bernardini, Maria A Montesu, Pierluigi Bruni, Montesu, Maria A, Megna, Matteo, Antonio Carpentieri, Bernardini, Nicoletta, Martino Carriero, Balestri, Riccardo, Sara Cacciapuoti, Laura Atzori, Atzori, Maria G, Michela Ortoncelli, Mugheddu, Cristina, Maria G Atzori, Ortoncelli, Michela, Addis, Gianmario, Atzori, Laura, Carriero, Martino, Rech, Giulia, Carpentieri, Antonio, Bruni, Pierluigi, Potenza, Concetta, Manuela Papini, Matteo Megna, Skroza, Nevena, Cristina Mugheddu, Giulia Rech, Cacciapuoti, Sara   +33 more
core   +1 more source